{"id":"glp-1-receptor-agonist","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–20","effect":"Constipation"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists bind to and activate GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. They simultaneously inhibit glucagon secretion from alpha cells and delay gastric emptying, reducing postprandial glucose spikes. These agents also promote satiety and weight loss through central nervous system effects.","oneSentence":"GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon release, and slow gastric emptying, thereby lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:01.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/GLP-1_receptor_agonist","title":"GLP-1 receptor agonist","extract":"Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake. GLP-1 analogs are molecules that are structurally almost identical to the endogenous GLP-1 hormone. Incretin mimetics are substances that mimic the actions of incretin hormones such as GLP-1 and GIP."},"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT06751589","phase":"EARLY_PHASE1","title":"A Study of a Weight Loss Intervention in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-19","conditions":"Endometrial Cancer","enrollment":36},{"nctId":"NCT07431086","phase":"PHASE2","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-16","conditions":"Overweight or Obesity","enrollment":120},{"nctId":"NCT06278285","phase":"NA","title":"Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-03-06","conditions":"Obesity","enrollment":40},{"nctId":"NCT06118203","phase":"","title":"Semaglutide Use in Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2022-01-02","conditions":"Pulmonary Embolism","enrollment":18},{"nctId":"NCT07495904","phase":"NA","title":"Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance","status":"NOT_YET_RECRUITING","sponsor":"Hellenic Mediterranean University","startDate":"2026-03-30","conditions":"Obesity","enrollment":130},{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT07491835","phase":"NA","title":"Effect of Lower Doses of Colonic Nutrient Supplementation on Appetite Hormones and Food Intake in Obese Adults","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2023-10-18","conditions":"Obesity & Overweight, Appetite Regulation","enrollment":16},{"nctId":"NCT07220473","phase":"PHASE2","title":"Tirzepatide to Slow Biological Aging","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-02-27","conditions":"Aging, LONGEVITY 1","enrollment":90},{"nctId":"NCT04128995","phase":"PHASE4","title":"Surgical or Medical Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-15","conditions":"Diabetes Mellitus, Type 2, Pediatric Obesity, Bariatric Surgery Candidate","enrollment":88},{"nctId":"NCT07448519","phase":"NA","title":"Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2023-06-13","conditions":"Obesity & Overweight, Appetite Regulation","enrollment":20},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07483801","phase":"PHASE4","title":"DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","status":"NOT_YET_RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-03","conditions":"Cardiovascular Diseases","enrollment":112},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT05119179","phase":"PHASE4","title":"Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-11-22","conditions":"PreDiabetes","enrollment":300},{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT07195994","phase":"NA","title":"A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes","status":"RECRUITING","sponsor":"QuickSilver Scientific","startDate":"2026-02-05","conditions":"Prediabetes / Type 2 Diabetes","enrollment":90},{"nctId":"NCT07272837","phase":"","title":"Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-04-01","conditions":"Type 2 Diabetes, Obesity, Semaglutide","enrollment":50},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Healthy Participants","enrollment":64},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT06982378","phase":"","title":"GLP-1 RA on Liver OMICS in MASLD","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-07","conditions":"NAFLD, Diabetes, Obesity","enrollment":30},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT07457424","phase":"","title":"Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College Dublin","startDate":"2022-02-17","conditions":"Metabolic Disease, Obesity & Overweight","enrollment":140},{"nctId":"NCT05965908","phase":"PHASE3","title":"Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-01-30","conditions":"Polycystic Ovary","enrollment":150},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT06851858","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-12","conditions":"Endocrinology, Diabetes, Type II, Obesity","enrollment":69},{"nctId":"NCT07169942","phase":"PHASE2","title":"Aleniglipron Phase 2 Body Composition Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","startDate":"2025-08-15","conditions":"Obesity, Overweight, or Chronic Weight Management","enrollment":71},{"nctId":"NCT07223216","phase":"PHASE1","title":"Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Biomea Fusion Inc.","startDate":"2025-10-23","conditions":"Obesity","enrollment":80},{"nctId":"NCT07001553","phase":"","title":"Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study","status":"COMPLETED","sponsor":"Australian Catholic University","startDate":"2025-05-28","conditions":"Obesity, Type 2 Diabetes Mellitus (T2DM)","enrollment":37},{"nctId":"NCT07443956","phase":"NA","title":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2026-02-24","conditions":"Psoriatic Arthritis (PsA), Obesity & Overweight","enrollment":45},{"nctId":"NCT07444073","phase":"","title":"Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","status":"NOT_YET_RECRUITING","sponsor":"National University of Singapore","startDate":"2026-02-02","conditions":"Aging, Obesity & Overweight","enrollment":440},{"nctId":"NCT04019197","phase":"PHASE2","title":"Effects of Semaglutide in HIV-Associated Lipohypertrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Western Reserve University","startDate":"2019-05-16","conditions":"HIV/AIDS, Lipohypertrophy, Obesity","enrollment":108},{"nctId":"NCT06795360","phase":"NA","title":"Weight Changes After Incretin-mimetics","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-12-01","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":52},{"nctId":"NCT07428746","phase":"PHASE3","title":"Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT07317115","phase":"NA","title":"Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","status":"RECRUITING","sponsor":"GT Metabolic Solutions, Inc.","startDate":"2026-03","conditions":"Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)","enrollment":20},{"nctId":"NCT07419854","phase":"PHASE4","title":"Restoring Facial Volume After GLP-1 Weight Loss With Radiesse","status":"RECRUITING","sponsor":"Kalpna Kay Durairaj, MD, FACS","startDate":"2026-02","conditions":"Volume Loss (Soft Tissue Ptosis or Atrophy )","enrollment":48},{"nctId":"NCT07280403","phase":"NA","title":"Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss","status":"COMPLETED","sponsor":"INQUIS Clinical Research","startDate":"2024-09-12","conditions":"Weight Loss","enrollment":60},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":"Diabetes Mellitus, Type 2","enrollment":230000},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT07104383","phase":"PHASE3","title":"VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)","status":"RECRUITING","sponsor":"Viking Therapeutics, Inc.","startDate":"2025-06-23","conditions":"Weight Loss","enrollment":1100},{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":"Muscle Wasting, Obesity & Overweight, Obesity","enrollment":164},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":"Major Depressive Disorder","enrollment":116},{"nctId":"NCT07228741","phase":"PHASE2","title":"Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Acute Lymphoblastic Leukemia, Obesity","enrollment":20},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":"Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":60},{"nctId":"NCT07382388","phase":"","title":"A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-01-28","conditions":"Psoriasis","enrollment":70},{"nctId":"NCT06467604","phase":"","title":"CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2024-11-01","conditions":"Obesity","enrollment":7},{"nctId":"NCT07270172","phase":"","title":"The MICRON Study - A Steno 1 Substudy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-10-27","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT07271043","phase":"NA","title":"Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics","status":"RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2026-01-01","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT07364175","phase":"NA","title":"A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-01","conditions":"Hypertension, Obesity & Overweight","enrollment":60},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT07373834","phase":"NA","title":"Tirzepatide and Muscle Outcomes in Obesity","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2026-01","conditions":"Obesity (Disorder)","enrollment":30},{"nctId":"NCT07163650","phase":"PHASE4","title":"Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-16","conditions":"Obesity, Weight Loss, Metabolic Surgery","enrollment":60},{"nctId":"NCT07370922","phase":"PHASE2","title":"Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-22","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":80},{"nctId":"NCT07360262","phase":"","title":"Gastric Emptying Recovery After GLP-1 RA Cessation","status":"COMPLETED","sponsor":"Wonkwang University Hospital","startDate":"2025-11-20","conditions":"Gastric Emptying, Gastroparesis, Preoperative Care","enrollment":186},{"nctId":"NCT06445075","phase":"PHASE2","title":"Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2024-05-21","conditions":"Overweight and Obesity","enrollment":102},{"nctId":"NCT07360457","phase":"","title":"GLP1 Analogues and the Risk of Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2026-02-01","conditions":"Osteoarthritis","enrollment":390},{"nctId":"NCT06132477","phase":"PHASE4","title":"Impact GLP-1 Agonists Following Bariatric","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-02-01","conditions":"Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus","enrollment":150},{"nctId":"NCT05788965","phase":"PHASE2, PHASE3","title":"Semaglutide in CFRD","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-10-16","conditions":"Cystic Fibrosis, Cystic Fibrosis-related Diabetes","enrollment":8},{"nctId":"NCT07104539","phase":"NA","title":"Strength Training Response of Muscle in GLP-1 Users","status":"RECRUITING","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2025-10-08","conditions":"Muscle Mass","enrollment":30},{"nctId":"NCT07242534","phase":"PHASE4","title":"Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","status":"RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2026-01-19","conditions":"Infertility, Obesity","enrollment":62},{"nctId":"NCT06518837","phase":"PHASE2","title":"Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-10-30","conditions":"Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer","enrollment":40},{"nctId":"NCT05984238","phase":"NA","title":"A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT06903923","phase":"","title":"Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-06-01","conditions":"Obesity in Children, Bone Strength, GLP - 1","enrollment":120},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07327281","phase":"PHASE1","title":"A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-12-18","conditions":"Hyperglycemia","enrollment":66},{"nctId":"NCT07218354","phase":"PHASE3","title":"Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":438},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT04520490","phase":"PHASE3","title":"Brain Activation and Satiety in Children 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-01-28","conditions":"Childhood Obesity","enrollment":63},{"nctId":"NCT07316816","phase":"NA","title":"Stanford Pediatric Healthy Weight Index","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-01-05","conditions":"Obesity & Overweight","enrollment":120},{"nctId":"NCT07314528","phase":"PHASE2","title":"Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"St. James's Hospital, Ireland","startDate":"2026-04","conditions":"Rectal Cancer Patients, Obesity &Amp; Overweight, Locally Advanced Rectal Cancer (LARC)","enrollment":42},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT07224880","phase":"","title":"Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists","status":"RECRUITING","sponsor":"Cytrellis Biosystems, Inc.","startDate":"2025-10-14","conditions":"glp1 Agonist, Gene Expression, Skin Laxity","enrollment":10},{"nctId":"NCT07226947","phase":"NA","title":"Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-24","conditions":"Obesity, Body Composition","enrollment":100},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT06693843","phase":"PHASE2","title":"A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","startDate":"2024-10-17","conditions":"Obesity, Overweight, or Chronic Weight Management","enrollment":220},{"nctId":"NCT07282041","phase":"PHASE2, PHASE3","title":"Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-12-17","conditions":"Intracranial Atherosclerosis, Stroke, Ischemic","enrollment":130},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT07293325","phase":"NA","title":"Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-02","conditions":"Adults With Simple Obesity","enrollment":66},{"nctId":"NCT05305794","phase":"PHASE3","title":"Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-07-12","conditions":"Double Diabetes","enrollment":76},{"nctId":"NCT07292519","phase":"PHASE2","title":"Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)","status":"NOT_YET_RECRUITING","sponsor":"South West Sydney Local Health District","startDate":"2026-01-15","conditions":"Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions","enrollment":46},{"nctId":"NCT07284511","phase":"PHASE2, PHASE3","title":"A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","status":"NOT_YET_RECRUITING","sponsor":"Melissa-Rosina Pasqua","startDate":"2026-01-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D","enrollment":105},{"nctId":"NCT07281196","phase":"","title":"Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea","status":"RECRUITING","sponsor":"Shanghai Fengxian District Central Hospital","startDate":"2025-01-01","conditions":"Sleep Apnea Syndrome (OSAS)","enrollment":15},{"nctId":"NCT07275697","phase":"PHASE4","title":"Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study","status":"NOT_YET_RECRUITING","sponsor":"Emma Svennberg","startDate":"2025-12-15","conditions":"Atrial Fibrillation (AF), Obesity & Overweight","enrollment":200},{"nctId":"NCT06069622","phase":"","title":"Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Overweight and Obesity","enrollment":30},{"nctId":"NCT07096739","phase":"NA","title":"Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1","status":"COMPLETED","sponsor":"Kate Farms Inc","startDate":"2025-08-01","conditions":"GLP-1 Concentration","enrollment":20},{"nctId":"NCT07127354","phase":"PHASE4","title":"The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-08-01","conditions":"GLP - 1, Bowel Preparation for Colonoscopy","enrollment":132},{"nctId":"NCT06003985","phase":"","title":"Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-08-29","conditions":"Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound","enrollment":354},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT06706284","phase":"PHASE4","title":"Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes","status":"RECRUITING","sponsor":"Marzieh Salehi","startDate":"2025-04-11","conditions":"Spinal Cord Injuries, Type 2 Diabetes","enrollment":50},{"nctId":"NCT03919929","phase":"PHASE2, PHASE3","title":"Treating PCOS With Semaglutide vs Active Lifestyle Intervention","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-05-03","conditions":"PCOS, Adolescent Obesity, NAFLD","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["semaglutide","liraglutide","dulaglutide","exenatide","GLP-1 agonists"],"phase":"marketed","status":"active","brandName":"GLP-1 receptor agonist","genericName":"GLP-1 receptor agonist","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon release, and slow gastric emptying, thereby lowering blood glucose levels. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":12,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}